miRagen Receives Validation of its miRNA Platform with Servier Collaboration
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 11 (Table of Contents)
Published: 2 Nov-2011
DOI: 10.3833/pdr.v2011.i11.1593 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
miRagen Therapeutics has signed a potential US$1 B research, development and commercialisation pact with France’s Les Laboratoires Servier for two of its preclinical-stage cardiovascular microRNA programmes, miR-208 and miR-15/195, plus an as yet unidentified target...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS